TY - JOUR T1 - European expert consensus on assessment and management of hospitalised exacerbations of COPD (CICERO ERS CRC) JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.4916 VL - 56 IS - suppl 64 SP - 4916 AU - Sanjay Ramakrishnan AU - Wim Janssens AU - Pierre Regis Burgel AU - Marco Contoli AU - F M E Franssen AU - Neil Greening AU - Timm Greulich AU - Iwein Gyselinck AU - Arturo Huerta AU - Jennifer Quint AU - Lowie Van Fleteren AU - Henrik Watz AU - Mona Bafadhel Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/4916.abstract N2 - Introduction: Despite being a high-risk event for morbidity and mortality, there is little consensus globally regarding the assessment and management of hospitalised exacerbations of COPD.Objectives: To find a consensus list of symptoms, physiological measures, clinical scores, patient questionnaires and investigations to be obtained at time of hospitalised COPD exacerbation and follow up.Methods: A modified online Delphi survey of importance, feasibility and suggested frequency on Likert scales was undertaken. Consensus and stability criteria were pre-defined.Results: 25 experts from 19 European countries participated. After completion of 2 rounds, consensus was achieved on 642 items (82%). Experts achieved consensus quickly on history and physical examination items. There was less consensus on other items. For example (see table 1), many scores and questionnaires were not considered essential in clinical practice. Experts could not agree on pulmonary function tests to perform routinely at time of hospitalisation nor the importance or frequency in which to perform echocardiography, CT scan and pulmonary function tests at follow-up. Experts could not agree on duration of treatment View this table:Table 1 Consensus items for clinical scores and questionnaires at time of COPD exacerbationConclusion: Despite being a major health burden, hospitalised COPD exacerbations are assessed and managed variably across Europe. Standardisation could impact clinical outcomes.Acknowledgements: This work was undertaken as part of the CICERO ERS clinical research collaborative.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4916.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -